@prefix prodottidellaricerca: . @prefix istituto: . @prefix prodotto: . istituto:CDS035 prodottidellaricerca:prodotto prodotto:ID135245 . @prefix modulo: . modulo:ID6312 prodottidellaricerca:prodotto prodotto:ID135245 . @prefix pubblicazioni: . @prefix unitaDiPersonaleInterno: . unitaDiPersonaleInterno:MATRICOLA9489 pubblicazioni:autoreCNRDi prodotto:ID135245 . unitaDiPersonaleInterno:MATRICOLA11035 pubblicazioni:autoreCNRDi prodotto:ID135245 . @prefix rdf: . prodotto:ID135245 rdf:type prodotto:TIPO1201 . @prefix retescientifica: . prodotto:ID135245 rdf:type retescientifica:ProdottoDellaRicerca . @prefix rdfs: . prodotto:ID135245 rdfs:label "Last advances in ultrasound molecular imaging (Contributo in volume (capitolo o saggio))"@en . @prefix xsd: . prodotto:ID135245 pubblicazioni:anno "2007-01-01T00:00:00+01:00"^^xsd:gYear . @prefix skos: . prodotto:ID135245 skos:altLabel "
Conversano F.; Casciaro S. (2007)
Last advances in ultrasound molecular imaging
Lupiensis Biomedical Publications, Lecce (Italia) in New Technology Frontiers in Minimally Invasive Therapies, 2007
"^^rdf:HTML ; pubblicazioni:autori "Conversano F.; Casciaro S."^^xsd:string ; pubblicazioni:paginaInizio "161"^^xsd:string ; pubblicazioni:paginaFine "171"^^xsd:string ; pubblicazioni:citta "Lecce, Italy"^^xsd:string ; pubblicazioni:titoloVolume "New Technology Frontiers in Minimally Invasive Therapies"^^xsd:string ; pubblicazioni:note "In: New Technology Frontiers in Minimally Invasive Therapies. pp. 161 - 171. Sergio Casciaro, B. Gersak (eds.). Lupiensis Biomedical Publications, 2007."^^xsd:string ; pubblicazioni:pagineTotali "11"^^xsd:string ; pubblicazioni:descrizioneSinteticaDelProdotto "Molecular imaging with ultrasound contrast agents relies on the detection of targeted microbubbles or acoustically active nanoparticles. Microbubbles employed for these purposes are retained in the targeted diseased tissue, where they produce an acoustic signal as a response to the incident ultrasound field. Targeting is generally accomplished through one of the two following strategies: attachment of disease-specific ligands to the microbubble shell or chemical modification of the shell itself, in order to facilitate its adherence to cells encountered in disease areas. As microbubbles cannot leave the intravascular space, the targeted disease process must be characterized by molecular changes in the vascular compartment to be imaged. Examples of such disease processes are inflammation, angiogenesis and thrombus formation. Recently, the introduction of smaller nanoparticle-based contrast agents has opened new perspectives for targeted imaging of diseases expressing their molecular markers beyond the vessel endothelial layer, including in particular various type of cancer cells. Techniques for microbubble targeting are reviewed in this chapter, together with the currently available results of their employment in molecular imaging. Most promising directions for next future developments deriving from the use of nanoparticle agents are also illustrated."^^xsd:string ; pubblicazioni:affiliazioni "CNR-IFC, Lecce, Italy."^^xsd:string ; pubblicazioni:titolo "Last advances in ultrasound molecular imaging"^^xsd:string ; pubblicazioni:inCollana "New Technology Frontiers in Minimally Invasive Therapies"^^xsd:string ; pubblicazioni:isbn "978-88-902880-1-2"^^xsd:string ; prodottidellaricerca:abstract "Molecular imaging with ultrasound contrast agents relies on the detection of targeted microbubbles or acoustically active nanoparticles. Microbubbles employed for these purposes are retained in the targeted diseased tissue, where they produce an acoustic signal as a response to the incident ultrasound field. Targeting is generally accomplished through one of the two following strategies: attachment of disease-specific ligands to the microbubble shell or chemical modification of the shell itself, in order to facilitate its adherence to cells encountered in disease areas. As microbubbles cannot leave the intravascular space, the targeted disease process must be characterized by molecular changes in the vascular compartment to be imaged. Examples of such disease processes are inflammation, angiogenesis and thrombus formation. Recently, the introduction of smaller nanoparticle-based contrast agents has opened new perspectives for targeted imaging of diseases expressing their molecular markers beyond the vessel endothelial layer, including in particular various type of cancer cells. Techniques for microbubble targeting are reviewed in this chapter, together with the currently available results of their employment in molecular imaging. Most promising directions for next future developments deriving from the use of nanoparticle agents are also illustrated."@en . @prefix ns11: . prodotto:ID135245 pubblicazioni:editore ns11:ID405 ; prodottidellaricerca:prodottoDi istituto:CDS035 , modulo:ID6312 ; pubblicazioni:autoreCNR unitaDiPersonaleInterno:MATRICOLA9489 , unitaDiPersonaleInterno:MATRICOLA11035 . ns11:ID405 pubblicazioni:editoreDi prodotto:ID135245 .